Trio in commercialization race for non-NSAID pain products
Soon there will be three animal health biotechnology companies commercializing new products for treating pain related to osteoarthritis in dogs. But why does this area need alternative treatments? And is there even a viable market for pain treatment in pets? Animal Pharm Editor Joseph Harvey casts his eye over this potentially burgeoning market.